MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Inflammation"

  • 2019 International Congress

    Plasma membrane Ca2+ Atpase 1 as a candidate to mediate the degeneration of dopaminergic neurons by inflammation in Parkinson’s disease

    B. Erhardt, MS. Marcora, A. Delella Ezcurra, J. Casabona, R. Tarelli, L. Frenkel, P. Bochicchio, D. Bodin, B. Silva, V. Cavaliere Candedo, MI. Farías, C. Ferrari, M. Allo, C. Höcht, A. Chernomoretz, E. Castaño, MC. Leal, F. Pitossi (Capital Federal, Argentina)

    Objective: To identify genes involved in the degeneration of the dopaminergic neurons (DN) of the substantia nigra (SN) by inflammation. Background: Parkinson’s disease (PD) is…
  • 2019 International Congress

    Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study

    H. Wilson, G. Dervenoulas, G. Pagano, R. Tyacke, J. Myers, R. Gunn, E. Rabiner, D. Nutt, M. Politis (London, United Kingdom)

    Objective: We aimed to evaluate the role of astroglia activation in Parkinson's disease (PD) using [11C]BU99008 PET, a novel radioligand with high specificity and selectivity…
  • 2019 International Congress

    Gut Feelings about Parkinson’s Disease: The Influence of the Gut Microbiota in a Rodent Model

    A. Gorecki, L. Preskey, M. Bakeberg, J. Kenna, C. Gildenhuys, S. Dunlop, F. Koengten, R. Anderton (Nedlands, Australia)

    Objective: The objective of this study was to investigate the gut microbiota in a pilot cohort of Australian patients with PD, and a rodent model…
  • 2019 International Congress

    Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington’s Disease: An in vivo [11C]BU99008 PET study

    H. Wilson, F. Niccolini, G. Dervenoulas, R. Tyacke, J. Myers, R. Gunn, D. Nutt, E. Rabiner, S. Tabrizi, M. Politis (London, United Kingdom)

    Objective: We aimed to evaluate the role of astroglia activation in Huntington’s disease gene expansion carriers (HDGECs) using [11C]BU99008 PET, a novel radioligand with high specificity and…
  • 2019 International Congress

    Long-Term Effects of LPS and Alcohol in Rats: A Model of Neuro-Degenerative Disease

    M. Schiess, M. Doursout, J. Campo, Z. Peng, A. Sundaresan, S. Umar (Lawrence, KS, USA)

    Objective: We postulate alterations of the intestinal barrier (or leaky guts) enhances inflammation, as well as the production of alpga (α)-synuclein which has characteristic pathological…
  • 2019 International Congress

    Serum mucosal chemokine levels in patients with Parkinson disease.

    S. Haji, W. Sako, N. Murakami, Y. Osaki, Y. Izumi (Tokushima, Japan)

    Objective: To investigate the relationship between mucosal chemokines including CXCL14 and CCL28) and impairment in motor/non-motor function among patients with Parkinson’s disease. Background: Parkinson disease…
  • 2019 International Congress

    CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson’s disease

    Y. Li, M. Niu, J. Liu (Shanghai, China)

    Objective: Activated microglia and increased cytokine levels could precede neurodegeneration in neuro-inflammation in A53T mice, and CXCL12 was found increased in plasma CNS-derived exosomes, which…
  • 2019 International Congress

    The role of the gut microbial dysbiosis and serum inflammatory profile for the discrimination of clinical subtypes in Parkinson’s disease

    I. Miliukhina, E. Ermolenko, E. Gracheva, A. Istomina, M. Kotyleva, E. Agapova, A. Suvorov (Saint-Petersburg, Russian Federation)

    Objective: To investigate whether clinical phenotypes can be predicted by the assessment of gut microbiome and serum inflammatory profile of PD patients. Background: Recent evidence…
  • 2019 International Congress

    Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist

    A. Pinna, G. Costa, M. Serra, M. Morelli (Monserrato, Italy)

    Objective: To evaluate whether an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A receptor antagonist preladenant prevent the onset of…
  • 2019 International Congress

    The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson’s disease

    I. Rektor, B. Vesely, N. Bohnen, E. Koritakova, E. Kurca, P. Valkovic (Brno, Czech Republic)

    Objective: To examine the contributions of systemic factors to clinically relevant cognitive decline in Parkinson’s disease (PD), we studied the impact of cardiometabolic and inflammatory…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 25
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley